Edit Drescher

Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study

Maxime Dougados, Désirée van der Heijde, Ying‐Chou Chen et al. · Annals of the Rheumatic Diseases · 2016 · 399 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +17

Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study

Désirée van der Heijde, Atul Deodhar, James Cheng‐Chung Wei et al. · Annals of the Rheumatic Diseases · 2017 · 369 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

Désirée van der Heijde, James Cheng‐Chung Wei, Maxime Dougados et al. · The Lancet · 2018 · 359 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +14

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate

Edward Keystone, Peter C. Taylor, Edit Drescher et al. · Annals of the Rheumatic Diseases · 2014 · 282 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

The Efficacy and Safety of Clazakizumab, an Anti–Interleukin‐6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis

Philip J. Mease, Alice B. Gottlieb, Alberto Berman et al. · Arthritis & Rheumatology · 2016 · 152 citations

Medicine, Pharmacology, Pharmacotherapy +15